vs
Side-by-side financial comparison of Protagonist Therapeutics, Inc (PTGX) and BRC Group Holdings, Inc. (RILY). Click either name above to swap in a different company.
BRC Group Holdings, Inc. is the larger business by last-quarter revenue ($188.3M vs $170.6M, roughly 1.1× Protagonist Therapeutics, Inc). Protagonist Therapeutics, Inc runs the higher net margin — 77.2% vs 47.9%, a 29.2% gap on every dollar of revenue. On growth, Protagonist Therapeutics, Inc posted the faster year-over-year revenue change (184.4% vs -21.9%).
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel peptide-based targeted therapies for unmet medical needs, primarily covering gastrointestinal disorders, inflammatory diseases and rare disease indications. Its lead product candidates target inflammatory bowel disease and other chronic immune-related conditions, with operations spanning global R&D and partnership collaborations.
PTGX vs RILY — Head-to-Head
Income Statement — Q4 FY2024 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $170.6M | $188.3M |
| Net Profit | $131.7M | $90.3M |
| Gross Margin | — | 79.5% |
| Operating Margin | 74.3% | 32.3% |
| Net Margin | 77.2% | 47.9% |
| Revenue YoY | 184.4% | -21.9% |
| Net Profit YoY | 381.7% | 1710.8% |
| EPS (diluted) | $2.01 | $2.78 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $188.3M | ||
| Q3 25 | — | $215.3M | ||
| Q2 25 | — | $188.2M | ||
| Q1 25 | — | $197.2M | ||
| Q4 24 | $170.6M | $241.0M | ||
| Q3 24 | — | $225.5M | ||
| Q2 24 | — | $256.0M | ||
| Q1 24 | $255.0M | $263.4M |
| Q4 25 | — | $90.3M | ||
| Q3 25 | — | $91.1M | ||
| Q2 25 | — | $139.5M | ||
| Q1 25 | — | $-10.0M | ||
| Q4 24 | $131.7M | $-5.6M | ||
| Q3 24 | — | $-284.4M | ||
| Q2 24 | — | $-433.6M | ||
| Q1 24 | $207.3M | $-49.2M |
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 83.7% | ||
| Q2 25 | — | 81.3% | ||
| Q1 25 | — | 81.4% | ||
| Q4 24 | — | 79.8% | ||
| Q3 24 | — | 82.1% | ||
| Q2 24 | — | 84.5% | ||
| Q1 24 | — | 85.3% |
| Q4 25 | — | 32.3% | ||
| Q3 25 | — | 30.4% | ||
| Q2 25 | — | 5.7% | ||
| Q1 25 | — | -31.2% | ||
| Q4 24 | 74.3% | -69.2% | ||
| Q3 24 | — | -36.4% | ||
| Q2 24 | — | -90.8% | ||
| Q1 24 | 80.9% | -6.1% |
| Q4 25 | — | 47.9% | ||
| Q3 25 | — | 42.3% | ||
| Q2 25 | — | 74.1% | ||
| Q1 25 | — | -5.1% | ||
| Q4 24 | 77.2% | -2.3% | ||
| Q3 24 | — | -126.1% | ||
| Q2 24 | — | -169.4% | ||
| Q1 24 | 81.3% | -18.7% |
| Q4 25 | — | $2.78 | ||
| Q3 25 | — | $2.91 | ||
| Q2 25 | — | $4.50 | ||
| Q1 25 | — | $-0.39 | ||
| Q4 24 | $2.01 | $-0.01 | ||
| Q3 24 | — | $-9.39 | ||
| Q2 24 | — | $-14.35 | ||
| Q1 24 | $3.26 | $-1.71 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $418.9M | $226.6M |
| Total DebtLower is stronger | — | $1.4B |
| Stockholders' EquityBook value | $675.3M | $-171.5M |
| Total Assets | $744.7M | $1.7B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $226.6M | ||
| Q3 25 | — | $184.2M | ||
| Q2 25 | — | $267.4M | ||
| Q1 25 | — | $138.3M | ||
| Q4 24 | $418.9M | $146.9M | ||
| Q3 24 | — | $159.2M | ||
| Q2 24 | — | $236.9M | ||
| Q1 24 | $322.6M | $190.7M |
| Q4 25 | — | $1.4B | ||
| Q3 25 | — | $1.3B | ||
| Q2 25 | — | $1.3B | ||
| Q1 25 | — | $1.4B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $-171.5M | ||
| Q3 25 | — | $-260.5M | ||
| Q2 25 | — | $-351.7M | ||
| Q1 25 | — | $-496.8M | ||
| Q4 24 | $675.3M | $-488.2M | ||
| Q3 24 | — | $-497.6M | ||
| Q2 24 | — | $-218.3M | ||
| Q1 24 | $560.4M | $228.4M |
| Q4 25 | — | $1.7B | ||
| Q3 25 | — | $1.7B | ||
| Q2 25 | — | $1.5B | ||
| Q1 25 | — | $1.5B | ||
| Q4 24 | $744.7M | $1.8B | ||
| Q3 24 | — | $2.2B | ||
| Q2 24 | — | $3.2B | ||
| Q1 24 | $629.3M | $5.0B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $184.2M | $26.2M |
| Free Cash FlowOCF − Capex | $182.8M | — |
| FCF MarginFCF / Revenue | 107.1% | — |
| Capex IntensityCapex / Revenue | 0.8% | — |
| Cash ConversionOCF / Net Profit | 1.40× | 0.29× |
| TTM Free Cash FlowTrailing 4 quarters | $101.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $26.2M | ||
| Q3 25 | — | $-60.6M | ||
| Q2 25 | — | $-25.6M | ||
| Q1 25 | — | $184.0K | ||
| Q4 24 | $184.2M | $-2.7M | ||
| Q3 24 | — | $19.5M | ||
| Q2 24 | — | $111.5M | ||
| Q1 24 | $-27.4M | $135.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $182.8M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $-27.7M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 107.1% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -10.9% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.8% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.1% | — |
| Q4 25 | — | 0.29× | ||
| Q3 25 | — | -0.66× | ||
| Q2 25 | — | -0.18× | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.40× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -0.13× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PTGX
Segment breakdown not available.
RILY
| Transferred At Point In Time | $101.4M | 54% |
| Wealth Management Segment | $30.7M | 16% |
| Corporate Finance Consulting And Investment Banking Fees | $27.1M | 14% |
| Services And Fees | $24.8M | 13% |
| Commissions Fees And Reimbursed Expenses | $4.8M | 3% |
